AtriCure, Inc.

NasdaqGM:ATRC Stock Report

Market Cap: US$1.5b

AtriCure Past Earnings Performance

Past criteria checks 0/6

AtriCure has been growing earnings at an average annual rate of 1.2%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 16.6% per year.

Key information

1.2%

Earnings growth rate

5.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate16.6%
Return on equity-8.4%
Net Margin-8.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb

Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb

US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How AtriCure makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:ATRC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24448-3928782
30 Jun 24430-4027581
31 Mar 24415-3727078
31 Dec 23399-3025874
30 Sep 23381-2524567
30 Jun 23366-2824162
31 Mar 23349-3823559
31 Dec 22330-4623157
30 Sep 22316-5622957
30 Jun 223035322154
31 Mar 222905221451
31 Dec 212745020549
30 Sep 212594519046
30 Jun 21243-5717445
31 Mar 21213-4915143
31 Dec 20207-4815143
30 Sep 20210-4614745
30 Jun 20212-5015745
31 Mar 20230-4616545
31 Dec 19231-3516741
30 Sep 19222-2315937
30 Jun 19216-2015035
31 Mar 19209-1714434
31 Dec 18202-2114035
30 Sep 18195-2013534
30 Jun 18187-2013033
31 Mar 18180-2712634
31 Dec 17175-2712134
30 Sep 17170-3311636
30 Jun 17166-3211137
31 Mar 17160-3410937
31 Dec 16155-3310536
30 Sep 16150-3610634
30 Jun 16143-3510232
31 Mar 16135-329729
31 Dec 15129-279126
30 Sep 15123-228523
30 Jun 15118-168322
31 Mar 15112-147820
31 Dec 14107-167819
30 Sep 1499-167417
30 Jun 1493-186815
31 Mar 1487-176514
31 Dec 1381-115713

Quality Earnings: ATRC is currently unprofitable.

Growing Profit Margin: ATRC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ATRC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare ATRC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).

Return on Equity

High ROE: ATRC has a negative Return on Equity (-8.37%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AtriCure, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charley JonesBarrington Research Associates, Inc.
Joanne WuenschBMO Capital Markets U.S. (Historical)
Michael GormanBTIG